# A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors

Source: https://onco.cc/trials/nct05965856/  
OnCo record `nct05965856` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of BL-B01D1 in bladder & urothelial cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.

## Summary

A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors is a phase 2 interventional study registered as NCT05965856 by Sichuan Baili Pharmaceutical Co., Ltd., with 52 participants planned, started 2023-12-11 and due to reach its primary completion in 2026-12. Interventions recorded: BL-B01D1 and SI-B003.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05965856
- Phase: 2
- Setting: A Phase II Clinical Study to Evaluate the Efficacy and Safety of SI-B003 Monotherapy and BL-B01D1+SI-B003 Combination Therapy (BL-B01D1+SI-B003) in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors
- Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
- Enrolled: 52

## Sources

- ClinicalTrials.gov NCT05965856: https://clinicaltrials.gov/study/NCT05965856

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- companies: [SystImmune / Sichuan Biokin](https://onco.cc/companies/systimmune/)

---
JSON: https://onco.cc/api/v1/entities/nct05965856.json